7 / 64
AFRICA
S5
CVJAFRICA • Volume 26, No 2, H3Africa Supplement, March/April 2015
Institutes of Health 2011 January 31; Available at: URL:
http://h3africa. org/images/PDF/h3africa_whitepaper.pdf.8.
Ford ES, Ajani UA, Croft JB,
et al
. Explaining the decrease in U.S.
deaths from coronary disease, 1980–2000.
N Engl J Med
2007;
356
(23):
2388–2398.
9.
Capewell S, O’Flaherty M. What explains declining coronary mortality?
Lessons and warnings.
Heart
2008;
94
(9): 1105–1108.
10. Cooper RS, Bovet P. Measures of health and disease in Africa: are
current methods giving us useful information about trends in cardiovas-
cular diseases?
Prog Cardiovasc Dis
2013;
56
(3): 270–277.
11. Ataklte F, Erqou S, Kaptoge S, Taye B, Echouffo-Tcheugui JB, Kengne
AP. Burden of undiagnosed hypertension in sub-saharan Africa: a
systematic review and meta-analysis.
Hypertension
2015;
65
(2): 291–298.
12. Kotowski IK, Pertsemlidis A, Luke A,
et al
. A spectrum of PCSK9
alleles contributes to plasma levels of low-density lipoprotein choles-
terol.
Am J Hum Genet
2006;
78
(3): 410–422.
13. Genovese G, Friedman DJ, Ross MD,
et al
. Association of trypanolytic
ApoL1 variants with kidney disease in African Americans.
Science
2010;
329
(5993): 841–845.
14. Genovese G, Friedman DJ, Pollak MR. APOL1 variants and kidney
disease in people of recent African ancestry.
Nat Rev Nephrol
2013;
9
(4): 240–244.
15. Parsa A, Kao WH, Xie D,
et al
. APOL1 risk variants, race, and progres-
sion of chronic kidney disease.
N Engl J Med
2013;
369
(23): 2183–2196.
16. Voight BF, Peloso GM, Orho-Melander M,
et al.
Plasma HDL choles-
terol and risk of myocardial infarction: a mendelian randomisation
study.
Lancet
2012;
380
(9841): 572–580.
17. Mensah GA, Kiley J, Mockrin SC,
et al
. National Heart, Lung, and
Blood Institute Strategic Visioning: Setting an Agenda Together for the
NHLBI of 2025.
Am J Public Health
2015; e1–e4.